LifeMD Reports Mixed Q4 Results, Guides for Q1 EBITDA Loss Amid Strategic Growth Investments

summarizeSummary

LifeMD reported Q4 revenue below estimates and guided for a Q1 2026 Adjusted EBITDA loss due to strategic growth investments, but highlighted a strong debt-free balance sheet and robust long-term revenue and EBITDA run-rate projections.

check_boxKey Events

• Q4 2025 Revenue Miss

  Reported Q4 2025 revenue of $46.9 million, a 4% increase year-over-year, but falling short of analyst estimates.

• Strong Balance Sheet

  Ended 2025 with $36.8 million in cash and no debt, providing significant financial flexibility for growth investments.

• Q1 2026 Guidance for EBITDA Loss

  Forecasts Q1 2026 revenue of $48-$49 million but an Adjusted EBITDA loss of $4-$5 million, attributed to strategic front-loaded patient acquisition investments.

• Strategic Growth Initiatives

  Successfully launched oral Wegovy and expanded women's health offerings, driving record patient sign-ups in Q1.

auto_awesomeAnalysis

LifeMD, Inc. reported fourth-quarter revenue that fell short of analyst estimates, and guided for an Adjusted EBITDA loss in Q1 2026 due to significant front-loaded investments in patient acquisition for its weight management (oral Wegovy) and women's health offerings. Despite the short-term profitability dip, the company exited 2025 with a strong balance sheet, including $36.8 million in cash and no debt. Management projects a return to profitability in Q2 2026 and anticipates strong annualized run-rate revenue exceeding $250 million and Adjusted EBITDA over $25 million by Q4 2026, driven by these strategic growth initiatives. Investors should monitor the execution of these growth strategies and the company's ability to achieve its ambitious Q4 2026 run-rate targets.